Loading organizations...
§ Private Profile · Leuven, Vlaams-Brabant, Belgium
AI medical software developer offering solutions for respiratory diagnosis, treatment, and clinical trials, focused on pulmonary function tests.
ArtiQ is a Leuven, Belgium-based healthcare technology company that develops artificial intelligence software to assist medical professionals in diagnosing, treating, and monitoring respiratory diseases. The software provider offers a business-to-business software-as-a-service platform that analyzes pulmonary function tests to deliver automated interpretations for conditions such as asthma and chronic obstructive pulmonary disease. Currently operating with fewer than 50 employees, the enterprise secured €1 million in seed funding at its launch to commercialize its CE-marked and ISO 13485-certified diagnostic tools. To expand its global reach in clinical trials and respiratory diagnostics, the firm has established strategic integrations and commercial partnerships with recognizable industry entities including Clario, Vyaire Medical, KBC Focus Fund, and Capricorn Partners. ArtiQ was officially founded in 2019 as a spin-off from research institution KU Leuven by co-founders Marko Topalovic, Wim Janssens, Marc Decramer, and Richard Dekhuijzen.
ArtiQ has raised $1.1M across 1 funding round.
ArtiQ has raised $1.1M in total across 1 funding round.
ArtiQ has raised $1.1M across 1 funding round. Most recently, it raised $1.1M Seed in June 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 19, 2019 | $1.1M Seed | — | Bart Swaelens, KBC, KU Leuven, University Hospitals Leuven | Announced |
ArtiQ has raised $1.1M in total across 1 funding round.
ArtiQ's investors include Bart Swaelens, KBC, KU Leuven, University Hospitals Leuven.